Daniel Uba, MD
Internal Medicine · Fayetteville, NCNPI 1578540860
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,528 of the $20,443 with a category attached, or 85.7%. It is spread thinly across 57 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $4,791 and has fallen 56.7% since, to $2,073 in 2025. Among internal medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,163 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- AstraZeneca$3K
- GSK$2K
- Medtronic$2K
- Genentech USA, Inc.$2K
- Lilly USA, LLC$1K
- plus $8K from 51 others
Across 58 payments — averaging $21,448 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.1M
- AbbVie$53K
- AstraZeneca$51K
- Sanofi US Services Inc.$21K
- Genentech, Inc.$17K
- Eli Lilly Export S.A. Puerto Rico Branch$5K
What the payments were for
- Travel & lodging$2,90914%
- Food & beverage$17,52886%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,443 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 375 | $333,771 |
| OzempicSemaglutide | 275 | $326,771 |
| FarxigaDapagliflozin Propanediol | 358 | $299,738 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 160 | $125,886 |
| TrulicityDulaglutide | 89 | $121,877 |
| LinzessLinaclotide | 160 | $101,044 |
| RybelsusSemaglutide | 79 | $84,811 |
| MounjaroTirzepatide | 74 | $83,196 |
| EliquisApixaban | 83 | $67,601 |
| Tresiba Flextouch U-200Insulin Degludec | 65 | $64,078 |
| JanuviaSitagliptin Phosphate | 51 | $53,838 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 49 | $40,928 |
| MyrbetriqMirabegron | 59 | $39,240 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 53 | $38,362 |
| TradjentaLinagliptin | 44 | $35,281 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Synjardy Xr, Glyxambi | $626 | $419,924489 claims |
| Novo NordiskOzempic, Rybelsus | $2,927 | $411,582354 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $2,610 | $347,965446 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,052 | $205,073163 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,931 | $170,149247 claims |
| AbbVieLinzess, Creon | $335 | $130,069171 claims |
| PfizerEliquis | $524 | $67,60183 claims |
| MerckJanuvia | $417 | $53,83851 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $522 | $40,92849 claims |
| Astellas Pharma US IncMyrbetriq | $22 | $39,24059 claims |
| Johnson & JohnsonXarelto | $379 | $34,33046 claims |
| BayerKerendia | $866 | $23,46928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Fayetteville
- Eugene WrightFayetteville$839K
- Frederick AsareFayetteville$86K
- Sandip PatelFayetteville$34K
- Nirmish ShahDurham$862K
- Saad UsmaniCharlotte$551K
- Bhakti PaulRaleigh$536K
- Mary KlotmanDurham$478K
- Manesh PatelDurham$435K
- Millie LongChapel Hill$374K
- Marc JohnsonCharlotte$342K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.